The BLOC1S6 Knockout SK-HEP-1 Polyclonal Cells constitute a genetically disrupted population of SK-HEP-1 human liver adenocarcinoma cells, generated through CRISPR/Cas9-mediated targeting of the BLOC1S6 gene. As a polyclonal knockout product, this population comprises a heterogeneous pool of cells carrying diverse CRISPR-induced mutations in BLOC1S6, providing a loss-of-function model for studying the gene??s role without the limitations of single-clone selection. This approach avoids clonal artifacts and maintains population-level diversity, which is particularly valuable for investigating complex intracellular trafficking pathways where subtle phenotypic variations may be masked in monoclonal lines. The knockout cells are supplied as a polyclonal pool, ready for expansion and downstream functional assays.
The SK-HEP-1 host cell line was originally established from the ascites of a patient with liver adenocarcinoma. As an adherent epithelial line, SK-HEP-1 cells display characteristics of both endothelial and hepatic origins, and they are widely employed in cancer biology research, including studies of metastasis, drug resistance, and intracellular transport. Despite their classification as adenocarcinoma cells, SK-HEP-1 retain a functional endosomal?Clysosomal system that makes them suitable for investigating organelle biogenesis. These cells express key components of the cellular trafficking machinery, enabling clear observation of BLOC-1-dependent processes following BLOC1S6 disruption.
BLOC1S6 encodes a subunit of the biogenesis of lysosome-related organelles complex-1 (BLOC-1), a multi-subunit complex that orchestrates cargo sorting and vesicle delivery to melanosomes, platelet dense granules, and other lysosome-related organelles. BLOC1S6 directly interacts with additional BLOC-1 subunits including BLOC1S1, BLOC1S2, BLOC1S3, PLDN, MUTED, and CNO, and the holocomplex cooperates with the adaptor protein complex AP-3 to direct melanosomal proteins such as TYRP1 and TYR to their target organelles. Furthermore, BLOC-1 is required for proper trafficking of platelet dense granule contents, notably ADP and serotonin, via pathways involving the small GTPases Rab32 and Rab38 and the SNARE protein VAMP7. Disruption of BLOC1S6 therefore dismantles BLOC-1 integrity, leading to mislocalization of cargo proteins and aberrant organelle formation.
In the SK-HEP-1 hepatic adenocarcinoma context, ablation of BLOC1S6 offers a unique platform to explore the intersection of lysosome-related organelle biogenesis and cancer cell biology. Although the primary role of BLOC1S6 is understood in specialized secretory organelles, emerging evidence indicates that lysosomal positioning and secretion are altered in cancer cells, contributing to invasion and drug resistance. By eliminating BLOC1S6 function, researchers can dissect how defective BLOC-1 activity affects the endolysosomal system in a tumor-relevant cell type. This model is particularly useful for examining whether loss of organelle biogenesis pathways exacerbates or mitigates malignant phenotypes, and for investigating potential therapeutic vulnerabilities linked to lysosome dysfunction in adenocarcinoma.
The polyclonal BLOC1S6 knockout SK-HEP-1 cells are suited for a broad range of applications, including Hermansky-Pudlak syndrome modeling, platelet dense granule disorder research, and investigations into melanosome biogenesis. Representative assays include western blotting and RT-qPCR to verify BLOC1S6 disruption and expression of related BLOC-1 subunits, immunofluorescence with lysosomal markers like LAMP1 and LAMP2 to assess organelle morphology, co-immunoprecipitation to examine BLOC-1 complex assembly, and cargo trafficking assays using TYRP1 as a reporter. Additionally, lysosomal pH measurement can evaluate functional consequences of BLOC-1 deficiency. For further technical details, custom bulk orders, or a personalized consultation, please contact Ascent Research.
